Citigroup Inc. Sells 5,678,717 Shares of Haemonetics Co. (NYSE:HAE)

Citigroup Inc. decreased its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 96.7% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 193,658 shares of the medical instruments supplier's stock after selling 5,678,717 shares during the period. Citigroup Inc. owned approximately 0.38% of Haemonetics worth $15,566,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Commonwealth Equity Services LLC boosted its stake in shares of Haemonetics by 3.3% in the 2nd quarter. Commonwealth Equity Services LLC now owns 3,673 shares of the medical instruments supplier's stock valued at $304,000 after purchasing an additional 117 shares in the last quarter. Vontobel Holding Ltd. boosted its stake in shares of Haemonetics by 3.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 4,878 shares of the medical instruments supplier's stock valued at $392,000 after purchasing an additional 180 shares in the last quarter. QRG Capital Management Inc. boosted its stake in shares of Haemonetics by 6.9% in the 2nd quarter. QRG Capital Management Inc. now owns 4,031 shares of the medical instruments supplier's stock valued at $333,000 after purchasing an additional 260 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Haemonetics by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 14,217 shares of the medical instruments supplier's stock valued at $1,176,000 after purchasing an additional 272 shares in the last quarter. Finally, Keene & Associates Inc. increased its stake in shares of Haemonetics by 3.0% in the third quarter. Keene & Associates Inc. now owns 10,174 shares of the medical instruments supplier's stock worth $818,000 after buying an additional 298 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on HAE shares. CL King started coverage on shares of Haemonetics in a research report on Friday, September 13th. They set a "buy" rating and a $116.00 price target for the company. Raymond James upgraded shares of Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 target price for the company in a report on Friday, November 8th. JMP Securities restated a "market outperform" rating and set a $125.00 price target on shares of Haemonetics in a report on Tuesday, August 13th. Needham & Company LLC reaffirmed a "buy" rating and set a $112.00 price target on shares of Haemonetics in a research report on Friday, November 15th. Finally, Bank of America began coverage on shares of Haemonetics in a research report on Wednesday, September 11th. They issued a "neutral" rating and a $85.00 target price for the company. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Haemonetics has an average rating of "Moderate Buy" and a consensus price target of $107.88.

Haemonetics Stock Down 0.7 %

Shares of NYSE:HAE traded down $0.64 during midday trading on Thursday, reaching $87.89. The company's stock had a trading volume of 430,973 shares, compared to its average volume of 556,030. The firm has a 50 day moving average of $79.73 and a 200-day moving average of $82.32. The firm has a market capitalization of $4.41 billion, a P/E ratio of 36.47, a PEG ratio of 1.37 and a beta of 0.32. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39. Haemonetics Co. has a 12-month low of $70.25 and a 12-month high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping analysts' consensus estimates of $1.09 by $0.03. The firm had revenue of $345.50 million for the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The company's revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.99 EPS. On average, research analysts anticipate that Haemonetics Co. will post 4.59 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.